
Contents

Preface.....	xi
About the Author	xv
Chapter 1 Safety pharmacology: Background, history, issues, and concerns	1
1.1 General versus safety pharmacology	2
1.2 History.....	4
1.3 Reasons for poor predictive performance.....	7
1.4 Why tiers?	8
1.5 Study designs and principles.....	9
1.5.1 Selection of methodology and species.....	9
1.6 Issues	12
1.7 Integral versus separate.....	13
1.8 Summary	15
References	15
Chapter 2 Regulatory requirements: ICH, FDA, EMA, and Japan.....	19
2.1 Regulatory requirements.....	19
References	23
Chapter 3 Principles of screening and study design.....	25
3.1 Introduction.....	25
3.2 Characteristics of screens	27
3.3 Uses of screens	30
3.4 Types of screens.....	32
3.5 Criterion: Development and use	32
3.6 Analysis of screening data	35
3.6.1 Univariate data.....	35
3.6.1.1 Control charts.....	35
3.6.1.2 Central tendency plots	37
3.6.2 Multivariate data.....	38
3.6.2.1 Analog plot	39
3.7 Study design.....	41

3.7.1	Animal model	41
3.7.2	Group size.....	42
3.7.3	Statistical design	42
3.7.3.1	Dose levels and test concentrations	42
References	42
Chapter 4	Cardiovascular system.....	45
4.1	Introduction.....	45
4.2	History.....	45
4.2.1	Special case (and concern)—QT prolongation	45
4.2.1.1	Regulatory developments.....	47
4.2.2	Patch-clamp studies using recombinant cells expressing hERG channels.....	57
4.2.3	hERG protein expression system.....	57
4.2.3.1	Relevance of hERG to QT prolongation.....	58
4.2.3.2	Expression and recording systems.....	58
4.2.4	Cardiovascular function testing.....	59
4.2.5	Conscious rodent, dog, and primate telemetry studies	64
4.2.5.1	Six-lead ECG measurement in the conscious dog	64
4.2.6	Systems for recording cardiac action potentials	65
4.2.6.1	Cloned human potassium channels	65
4.2.6.2	Cardiac action potential <i>in vitro</i> —Purkinje fibers	65
4.2.6.3	Monophasic action potential in anesthetized guinea pigs.....	65
4.2.6.4	ECG by telemetry in conscious guinea pigs	65
4.2.6.5	Hemodynamics and ECG in anesthetized or conscious dogs or primates	66
4.3	Summary	66
References	66
Chapter 5	Central nervous system	69
5.1	Core battery CNS procedures.....	72
5.1.1	General behavioral observation.....	72
5.1.2	Functional observational battery	73
5.2	Rat	74
5.2.1	Observational assessments	74
5.2.2	Locomotor activity.....	75
5.2.3	Motor coordination.....	75
5.2.4	Pain sensitivity.....	76
5.2.5	Convulsive threshold.....	76
5.3	Dog.....	77
5.3.1	Neurobehavioral screen.....	77

5.4	Sleep induction and interaction with hypnotics	81
5.5	Higher cognitive function	81
5.5.1	Passive avoidance	81
5.5.2	Morris maze	82
5.5.2.1	Materials.....	82
5.5.2.2	Set up apparatus and begin acquisition testing ..	83
5.5.2.3	Continue trials.....	83
5.6	Isolated tissue assays.....	84
5.6.1	Electrophysiology methods.....	84
5.7	CNS function: Electroencephalography.....	86
5.8	Neurochemical and biochemical assays	87
	References	88
	Chapter 6 Respiratory system.....	91
6.1	Plethysmography.....	96
6.2	Design of respiratory function safety studies	99
6.2.1	General considerations	99
6.2.2	Study design.....	99
6.2.3	Capnography.....	100
6.3	Study design considerations	101
6.3.1	Dose selection.....	101
6.3.2	Species selection.....	101
6.4	Summary	101
	References	102
	Chapter 7 Renal function.....	105
7.1	Major functions of the kidney	106
7.2	Acute renal failure.....	108
7.3	Functional reserve of the kidney.....	109
7.4	Clearance.....	109
7.5	Free water clearance and renal concentrating ability	114
7.5.1	Renal blood flow	116
7.5.2	Fractional excretion of sodium	116
7.6	Clinical chemistry measures	116
7.7	Animal models.....	117
7.7.1	Rat	117
7.7.2	Dog.....	118
7.8	Examples of species differences in drug sensitivity.....	118
	References	119
	Chapter 8 The gastrointestinal system.....	121
8.1	Drug-induced alterations of GI transit or motility	122
8.2	Gastrointestinal function.....	122
8.3	Assessment of intestinal transit.....	124

8.4	Determination of intestinal absorption.....	126
8.4.1	Methods of administering test substance.....	126
8.4.2	Methods for quantitating degree of absorption.....	127
8.4.2.1	Appearance in systemic fluids.....	127
8.5	Gastric emptying rate and gastric pH changes: A new model.....	130
8.6	Effects of drugs on gut immune system (jejunum, ileum, colon)...	131
8.7	Candidate drugs to evaluate for effects on gut immune system...	131
8.8	Conclusions	132
	References	132
Chapter 9 The immune system.....		135
9.1	Introduction to the immune system and adverse modulation activities of drugs	135
9.1.1	Passive cutaneous anaphylaxis:	
	Test for potential antigenicity of compound	137
9.1.1.1	Test method for pulmonary sensitization.....	140
9.1.2	Center for Drug Evaluation and Research guidance for investigational new drugs.....	141
9.2	Overview of the immune system.....	142
9.3	Immunotoxic effects.....	148
9.3.1	Immunosuppression	149
9.3.2	Immunosuppressive drugs	151
9.3.2.1	Antimetabolites.....	151
9.3.2.2	Glucocorticosteroids.....	154
9.3.2.3	Cyclosporine.....	155
9.3.2.4	Nitrogen mustards.....	155
9.3.2.5	Estrogens.....	156
9.3.2.6	Heavy metals.....	156
9.3.2.7	Antibiotics.....	157
9.3.3	Immunostimulation	157
9.3.3.1	Hypersensitivity	159
9.3.3.2	Photosensitization.....	164
9.3.3.3	Autoimmunity.....	165
	References	169
	Appendix A: Acronyms	175
	Appendix B: Laboratories conducting safety pharmacology testing.....	179